报告题目：Photo-modulated Ocular Drug Delivery of Biomacromolecular Therapeutics
报告时间：9月25日 14:00
报告地点：15楼会议室2
报告人：Tim Hughes 教授
报告人简介：Timothy Hughes博士是澳大利亚联邦科学与工业组织（CSIRO）的首席科学家，主任研究员，他的研究领域主要包括设计和合成生物医用聚合物，尤其是眼科生物医用高分子。他1997年毕业于澳大利亚莫纳什大学，获得有机化学专业博士学位，在CSIRO博士后期间就开始了眼科生物材料的研究。在与CSIRO视觉合作研究中心的合作中，Timothy Hughes博士研究开发了多孔含氟聚醚作为角膜屈光的植入体，聚硅氧烷作为可注射人工晶状体，这两项技术目前已在 Adventus Technologies Inc 公司的帮助下实现商业化，他主持开发的CIBA Vision 长戴型的角膜接触镜已在全球推广。同时，Timothy Hughes博士还在其他生物材料研究领域如手术粘合剂，角膜接触镜涂层，组织工程支架有一定的成就。他目前还在多家公司担任专业技术顾问
报告摘要：
Age-related macular degeneration (AMD) is the leading cause of blindness in Australia today.
1. The only way to save vision requires ongoing monthly injections of biomacromolecular anti-angiogenics to the eye with.
2. This invasive procedure, with the potential for sight threatening complications, has obvious negative impacts on patient’s quality of life as well as posing a major burden on the health care system. A drug delivery system that serves as a reservoir to enable sustained release or ‘on-demand’ release of therapeutics would be beneficial, since it will significantly reduce the number of injections into the back of the eye.
3. Here we report the fabrication of a photo-responsive drug delivery system based on a thermo-responsive polymer containing light sensitive nanoparticles (LSNPs) and therapeutic payloads.4,5 The release of different payloads, ranging from small molecules (doxorubicin, trimacinolone acetonide) to biomacromolecules (lysozyme, bovine serum albumin, and IgG/antibody), upon light stimulation was evaluated in vitro.
Released lysozyme, bevacizumab, and ranibizumab from this formulation exhibited above 85% biological activities after their exposure to light. The formulation did not show in vitro toxicity to ocular cells, and can be injected subconjunctivally through a 30-gauge needle to the rabbit as an ocular drug depot. Due to its minimum toxicity, tuneable drug release rates and high versatility, this photo-modulated drug delivery system has a potential to improve the treatment of ocular diseases.
欢迎感兴趣的科研人员参加！
